Utility-weighted modifed rankin scale as primary outcome in stroke trials a simulation study
Stroke , Volume 49 - Issue 4 p. 965- 971
Background and Purpose-The utility-weighted modifed Rankin Scale (UW-mRS) has been proposed as a new patientcentered primary outcome in stroke trials. We aimed to describe utility weights for the mRS health states and to evaluate the statistical effciency of the UW-mRS to detect treatment effects in stroke intervention trials. Methods-We used data of the 500 patients enrolled in the MR CLEAN (Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands). Utility values were elicited from the EuroQol Group 5-Dimension Self-Report Questionnaire assessed at 90 days after inclusion, simultaneously with the mRS. Utility weights were determined by averaging the utilities of all patients within each mRS category. We performed simulations to evaluate statistical effciency. The simulated treatment effect was an odds ratio of 1.65 in favor of the treatment arm, similar for all mRS cutoffs. This treatment effect was analyzed using 3 approaches: linear regression with the UW-mRS as outcome, binary logistic regression with a dichotomized mRS (0-1/2-6, 0-2/3-6, and 0-4/5-6), and proportional odds logistic regression with the ordinal mRS. The statistical power of the 3 approaches was expressed as the proportion of 10 000 simulations that resulted in a statistically signifcant treatment effect (P=0.05). Results-The mean utility values (SD) for mRS categories 0 to 6 were: 0.95 (0.08), 0.93 (0.13), 0.83 (0.21), 0.62 (0.27), 0.42 (0.28), 0.11 (0.28), and 0 (0), respectively, but varied substantially between individual patients within each category. The UW-mRS approach was more effcient than the dichotomous approach (power 85% versus 71%) but less effcient than the ordinal approach (power 85% versus 87%). Conclusions-The UW-mRS as primary outcome does not capture individual variation in utility values and may reduce the statistical power of a randomized trial.